

Dear Payer,

Bristol Myers Squibb Canada (BMS) is currently experiencing a constrained supply of ORENCIA® SC (abatacept for subcutaneous injection 125 mg/mL) due to an increase in demand. There are no safety or efficacy issues impacting ORENCIA® SC currently in Canadian pharmacies or personal supplies. This constrained supply situation does not affect the supply of ORENCIA® intravenous (IV) available in clinics across Canada.

March 19, 2024

**Constrained supply of
ORENCIA® SC (abatacept
for subcutaneous
injection 125mg/mL)**

BMS is working to manage existing stocks of ORENCIA® SC to mitigate the effects of this situation and has posted the information about the limited availability on the Canadian Drug Shortage Database (<https://www.drugshortagescanada.ca/>). As part of our effort to ensure equitable access to all patients, we recommend patients not be dispensed more than 4 weeks of treatment per pharmacy visit until further notice. The company will provide updated information as it becomes available. BMS is committed to working closely with authorities to ensure its medicines are accessible to Canadians.

Indication:

ORENCIA® (abatacept) is indicated for Adult Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)/Juvenile Rheumatoid Arthritis (JRA), Adult Psoriatic Arthritis (PsA), and prophylaxis for Acute Graft versus Host Disease. See product monograph: https://www.bms.com/assets/bms/ca/documents/productmonograph/ORENCIA_EN_PM.pdf.


Shortage includes:

Single-dose, disposable Prefilled Syringes with BD UltraSafe Passive™ Needle Guard with Flange Extenders for Subcutaneous Administration, 125mg/ml

BMS will work to minimize disruptions to ORENCIA® SC patients through the ORENCIA® Response Program (ORP). Should the constrained supply require a temporary switch to ORENCIA® IV you can connect with the ORP support line at 1 866-949-9927.

If you have questions or require additional information regarding the shortage of ORENCIA® SC, please contact our Medical Information Department at 1-866-463-6267 and medical.canada@bms.com.

Sincerely,



François Villeneuve
Head, Market Access & Pricing